Prima BioMed Ltd (PBMD) Analyst Price Target Changes By Brenton...

Prima BioMed Ltd (PBMD) Analyst Price Target Changes
By Brenton Akerman / in US Broker Ratings / on Friday, 01 Apr 2016 11:55 AM / 0 Comments

Recently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Prima BioMed Ltd (PBMD).
The most recent broker reports which have been released note that 1 analyst has a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 analysts “underperform” and 0 analysts “sell”.
Recent analyst ratings and price targets:
12/30/2015 – Roth Capital began new coverage on Prima BioMed Ltd giving the company a “buy” rating. They now have a USD 6 price target on the stock.
12/03/2015 – FBR Capital Markets began new coverage on Prima BioMed Ltd giving the company a “outperform” rating. They now have a USD 6 price target on the stock.
10/14/2015 – H.C. Wainwright began new coverage on Prima BioMed Ltd giving the company a “buy” rating. They now have a USD 3 price target on the stock.
Prima BioMed Ltd has a 50 day moving average of 0.89 and a 200 day moving average of 1.07. The stock’s market capitalization is 62.28M, it has a 52-week low of 0.42 and a 52-week high of 6.48.
The share price of the company (PBMD) was up +2.56%, with a high of 0.98 during the day and the volume of Prima BioMed Ltd shares traded was 87618.

Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Company’s product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Company’s other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.